Concurrent Chemo-radiation As a Means of Achieving Pathologic Complete Response in Triple Negative Breast Cancer

Maryam Nemati Shafaee; Shalini Makawita; Bora Lim; Matthew J Ellis; Michelle S Ludwig

doi:10.1016/j.clbc.2021.12.001

Concurrent Chemo-radiation As a Means of Achieving Pathologic Complete Response in Triple Negative Breast Cancer

Clin Breast Cancer. 2022 Jun;22(4):e536-e543. doi: 10.1016/j.clbc.2021.12.001. Epub 2021 Dec 14.

Authors

Maryam Nemati Shafaee¹, Shalini Makawita², Bora Lim¹, Matthew J Ellis³, Michelle S Ludwig⁴

Affiliations

¹ Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX.
² MD Anderson Cancer Center, Houston, TX.
³ Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX; Lester and Sue Smith Breast Center, Cancer Center.
⁴ Cancer Center, Baylor College of Medicine, Houston, TX.

PMID: 35184934
DOI: 10.1016/j.clbc.2021.12.001

Abstract

Management of triple negative breast cancer (TNBC) that is resistant to chemotherapy remains a challenge. Many studies have investigated the unconventional approach of concurrent chemotherapy with radiation in management of TNBC that is resistant to neoadjuvant anthracycline and taxane containing chemotherapy. Various chemotherapies have been used as radiosensitizers. In this report we summarize the published literature and highlight clinical trials that pertain to management of TNBC.

Keywords: Concurrent Chemo-radiation; Pathologic complete response; Primary resistant TNBC; Triple negative breast cancer.

MeSH terms

Anthracyclines / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Breast Neoplasms* / drug therapy
Female
Humans
Neoadjuvant Therapy
Triple Negative Breast Neoplasms* / drug therapy
Triple Negative Breast Neoplasms* / pathology

Substances

Anthracyclines